Vericel (VCEL) Expected to Announce Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Vericel to post earnings of $0.45 per share and revenue of $92.6640 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Vericel Stock Performance

Shares of VCEL stock opened at $38.25 on Wednesday. The company’s fifty day moving average price is $37.07 and its 200-day moving average price is $36.12. The stock has a market cap of $1.93 billion, a PE ratio of 159.38 and a beta of 1.24. Vericel has a 12 month low of $29.24 and a 12 month high of $55.41.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on VCEL shares. Zacks Research cut shares of Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Truist Financial dropped their price target on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Institutional Trading of Vericel

Institutional investors and hedge funds have recently modified their holdings of the business. Kestra Advisory Services LLC bought a new position in shares of Vericel during the fourth quarter valued at $27,000. Quarry LP purchased a new position in Vericel in the 4th quarter worth about $31,000. Truvestments Capital LLC lifted its stake in Vericel by 175.4% during the 4th quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 977 shares during the period. Empowered Funds LLC purchased a new stake in shares of Vericel during the 4th quarter valued at about $58,000. Finally, Osaic Holdings Inc. grew its stake in shares of Vericel by 13.7% in the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 353 shares during the period.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.